Cargando…

Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study

Background: The majority of therapies have generally targeted fasting glucose control, and current mealtime insulin therapies have longer time action profiles than that of endogenously secreted insulin. The primary purpose of this study was to assess both glucose time-in-range (TIR: 70–180 mg/dL) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akturk, Halis Kaan, Snell-Bergeon, Janet K., Rewers, Amanda, Klaff, Leslie J., Bode, Bruce W., Peters, Anne L., Bailey, Timothy S., Garg, Satish K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161328/ https://www.ncbi.nlm.nih.gov/pubmed/30207748 http://dx.doi.org/10.1089/dia.2018.0200

Ejemplares similares

Hypoglycaemia is reduced with use of inhaled Technosphere(®) Insulin relative to insulin aspart in type 1 diabetes mellitus
por: Seaquist, E. R., et al.
Publicado: (2019)

Place of technosphere inhaled insulin in treatment of diabetes
por: Mikhail, Nasser
Publicado: (2016)

Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents
por: Rosenstock, Julio, et al.
Publicado: (2008)

Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin
por: Levin, Philip A, et al.
Publicado: (2016)

Comprehensive Pulmonary Safety Review of Inhaled Technosphere(®) Insulin in Patients with Diabetes Mellitus
por: McGill, Janet B., et al.
Publicado: (2020)

A Population Dose–Response Model for Inhaled Technosphere Insulin Administered to Healthy Subjects
por: Rüppel, D, et al.
Publicado: (2017)

Case Report: Efficient Avoidance of Hospitalization for Diabetic Ketosis Utilizing Technosphere Inhaled Insulin
por: Bell, David S. H., et al.
Publicado: (2020)

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes
por: Bowering, K., et al.
Publicado: (2018)

Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
por: Grant, Marshall, et al.
Publicado: (2021)

Role of Mobile Technology to Improve Diabetes Care in Adults with Type 1 Diabetes: The Remote-T1D Study iBGStar(®) in Type 1 Diabetes Management
por: Garg, Satish K., et al.
Publicado: (2017)

Time–Action Profile of Technosphere Insulin in Children with Type 1 Diabetes
por: Haller, Michael J., et al.
Publicado: (2023)

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
por: Bode, Bruce W., et al.
Publicado: (2017)

Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator
por: Visentin, Roberto, et al.
Publicado: (2016)

Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast‐acting insulin aspart compared with insulin aspart
por: Basu, Ananda, et al.
Publicado: (2018)

Insulin Resistance, Defective Insulin-Mediated Fatty Acid Suppression, and Coronary Artery Calcification in Subjects With and Without Type 1 Diabetes: The CACTI Study
por: Schauer, Irene E., et al.
Publicado: (2011)

Assessing the relationship between low-calorie sweetener use and quality of life measures in adults with type 1 diabetes
por: Akturk, Halis K, et al.
Publicado: (2023)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Early Diabetic Nephropathy: A complication of reduced insulin sensitivity in type 1 diabetes
por: Bjornstad, Petter, et al.
Publicado: (2013)

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)
por: Garg, Satish K., et al.
Publicado: (2020)

New-onset insulin-dependent diabetes due to nivolumab
por: Zaied, Ali A, et al.
Publicado: (2018)

Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial
por: Thrasher, James, et al.
Publicado: (2020)

Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study
por: Kumar, S., et al.
Publicado: (2016)

Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial
por: Garg, Satish K., et al.
Publicado: (2020)

Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits
por: Pauley, Meghan E., et al.
Publicado: (2022)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Haryana cohort of the A(1)chieve study
por: Kalra, Sanjay, et al.
Publicado: (2013)

Associations of Dietary Antioxidants with Glycated Hemoglobin and Insulin Sensitivity in Adults with and without Type 1 Diabetes
por: Basu, Arpita, et al.
Publicado: (2022)

Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations
por: Leahy, John (Jack) L, et al.
Publicado: (2019)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018)

Intranasal Insulin Enhances Postprandial Thermogenesis and Lowers Postprandial Serum Insulin Levels in Healthy Men
por: Benedict, Christian, et al.
Publicado: (2011)

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
por: Onishi, Yukiko, et al.
Publicado: (2016)

Lipoprotein Subfraction Cholesterol Distribution Is Proatherogenic in Women With Type 1 Diabetes and Insulin Resistance
por: Maahs, David M., et al.
Publicado: (2010)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

Racial Disparities in Diabetes Technology Adoption and Their Association with HbA1c and Diabetic Ketoacidosis
por: Conway, Rebecca Baqiyyah, et al.
Publicado: (2023)

Geek and hacker stories: code, culture and storytelling from the technosphere
por: Alleyne, Brian
Publicado: (2018)

Planetary Scale Information Transmission in the Biosphere and Technosphere: Limits and Evolution
por: Lingam, Manasvi, et al.
Publicado: (2023)

Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin
por: Matheu, Victor, et al.
Publicado: (2005)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022)

Meta-analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus
por: Heller, Simon, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_f6d1pu6h5jhgk446pg3um78l7r